EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim

Tomonori Makiguchi iD, Haruka Odagiri, Hisashi Tanaka iD, Kageaki Taima, Sadatomo Tasaka

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Tomonori Makiguchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki City, Japan. Hauptthemen laut MEDLINE: Docetaxel, Filgrastim, Polyethylene Glycols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with non‐small cell lung cancer (NSCLC) receiving docetaxel (DTX) and ramucirumab (RAM) regimen frequently experience febrile neutropenia (FN). We aimed to clarify the incidence rate and predictive factors of FN under prophylactic pegfilgrastim.

Methods

Fifty‐four patients with NSCLC received DTX + RAM from 2018 to 2023 in our hospital. Age, gender, performance status (PS), treatment line, prior thoracic irradiation, body mass index (BMI), neutrophil count at baseline (BNC) and the lowest neutrophil count (LNC), serum albumin, and incidence of FN were recorded. The correlation between BNC and LNC was analyzed. We evaluated the association between BNC and FN using logistic regression analysis. The baseline characteristics of two groups stratified by the cutoff BNC using the ROC curve were compared.

Results

All the patients received prophylactic pegfilgrastim. Three (5.5%) patients experienced FN. There was a significant correlation between BNC and LNC ( r s = 0.43, p = 0.0003). BNC and cardiovascular disease were significantly associated with FN (odds ratio 0.998, p = 0.0151 and odds ratio 28.64, p = 0.034). The receiver operating characteristic curve showed the cutoff value of BNC was 3000/μL (AUC 0.88). There was no significant difference in other baseline characteristics between the patients with BNC of 3000/μL or more and those with BNC less than 3000/μL.

Conclusion

Our data showed the incidence rate of FN receiving DTX + RAM with prophylactic pegfilgrastim was 5.5%. Despite prophylactic pegfilgrastim, BNC was correlated with LNC and might be predictive of FN. We should be careful of BNC even if it meets the criteria for starting DTX + RAM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelFilgrastimPolyethylene GlycolsAntibodies, Monoclonal, HumanizedFebrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsNeutrophilsLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansMaleFemaleRamucirumabMiddle AgedAgedRetrospective Studies

Stichwörter der Autor:innen

baseline neutrophil countdocetaxelfebrile neutropeniapegfilgrastimramucirumab

Substanzen

pegfilgrastimDocetaxelFilgrastimRamucirumabPolyethylene GlycolsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki City, Japan.

ORCID-Profile: Tomonori Makiguchi, Hisashi Tanaka

Zitieren

APA

Makiguchi, T., Odagiri, H., Tanaka, H., Taima, K., & Tasaka, S. (2025). Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70099

Vancouver

Makiguchi T, Odagiri H, Tanaka H, Taima K, Tasaka S. Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70099

BibTeX
@article{Makiguchi2025,
  author = {Makiguchi, Tomonori and Odagiri, Haruka and Tanaka, Hisashi and Taima, Kageaki and Tasaka, Sadatomo},
  title = {Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70099}
}
Kostenlos starten →